secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001140361-25-041805
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech Q3 net loss $9.0M; Phase 2 mOS 39.3 months; seeks accelerated approval
--------------------------------------------------------------------------------

- Q3 net loss $9.0M ($0.19/share) vs $10.7M ($0.29) YoY; R&D expenses down to $4.6M.
- Cash $26.2M at Sep 30, 2025 vs $41.7M Dec 2024; raised ~$5.3M on Nov 12 stock/warrant sale.
- VERSATILE-002 Phase 2 complete: mOS 39.3 months, PFS 6.3 months in CPS≥1 HNSCC patients.
- Plans to amend VERSATILE-003 Phase 3 to seek accelerated approval with PFS as surrogate endpoint.
- Colorectal cancer cohort of PDS01ADC met Stage 2 expansion criteria (≥6 of 9 objective responses).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125041805/0001140361-25-041805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125041805/ef20058907_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-041805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer